Association between changes in the mRNA expression of platelet-activating factor receptor in peripheral blood mononuclear cells and progression of diabetic nephropathy

  • Sahar Ghavidel Darestani
  • Mihoko KuranoEmail author
  • Atsushi Shinnakasu
  • Kiyoaki Yamamoto
  • Yukari Dochi
  • Kayo Uemura
  • Yuko Ikeda
  • Aiko Arimura
  • Hiroshi Arimura
  • Akira Kikuchi
  • Hiroshi Hashiguchi
  • Takahisa Deguchi
  • Yoshihiko Nishio
Original Article



Several studies have recently pointed out the role of many inflammatory mediators in the progression of diabetes complications. We had previously demonstrated that mRNA expression of platelet-activating factor receptor (PAFR) in peripheral blood mononuclear cells (PBMCs) was associated with urinary albumin to creatinine ratio (ACR) and forearm flow-mediated dilatation in patients with type 2 diabetes. In an attempt to elucidate this association, patients were followed up for 1 year.

Materials and methods

We recruited 95 patients from the hospital outpatient clinic, among whom 86 were followed up for 1 year (normoalbuminuria: 40 patients, microalbuminuria: 25 patients, macroalbuminuria: 21 patients). We then measured their baseline and 12 month characteristics and collected blood samples to extract PBMCs and measure gene expressions.


Despite higher mRNA expression of PAFR in PBMCs among patients with macroalbuminuria, the rise in its value was not associated with biomarkers of nephropathy, while baseline values were not associated with progression of nephropathy. Moreover, changes in mRNA expression of PAFR were correlated with changes in ACR in all patients (r = 0.225, p = 0.037) and estimated glomerular filtration rate in patients with macroalbuminuria (r =  − 0.438, p = 0.047) during the follow-up period.


Our findings indicate that even though no causal relationship exists between diabetic nephropathy and elevated expression of PAFR in PBMCs, their close association signifies the presence of another common mechanism that could induce both events. Given these findings, the PAF/PAFR interaction could clarify corresponding mechanisms involved in diabetic complications.


Diabetic nephropathy Follow-up study Macrovascular complication Inflammation 



We wish to thank Joint Research Laboratory, Kagoshima University Graduate School of Medical and Dental Sciences, for the use of their facilities. We also wish to express our thanks to Kagoshima University Hospital clinical laboratory center, for the analysis of blood cells, and the laboratory research assistant Ms. A. Mihara. The authors would also like to thank the patients who took part in the clinical trial and the collaborators at the clinics. The authors would like to thank Enago ( for the English language review.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest associated with this manuscript.

Ethical approval

All the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

Informed consent

Informed consents were obtained from all participants for being included in the study.

Supplementary material

13340_2019_394_MOESM1_ESM.docx (16 kb)
Supplementary file1 (DOCX 15 kb)


  1. 1.
    Danaei G, Lu Y, Singh GM, et al. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014;2(8):634–47.CrossRefGoogle Scholar
  2. 2.
    Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int. 2003;63(1):225–32.CrossRefGoogle Scholar
  3. 3.
    Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85–97.CrossRefGoogle Scholar
  4. 4.
    Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–426.CrossRefGoogle Scholar
  5. 5.
    Gaita D, Mihaescu A, Schiller A. Of heart and kidney: a complicated love story. Eur J Prev Cardiol. 2014;21(7):840–6.CrossRefGoogle Scholar
  6. 6.
    Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed Res Int. 2014;2014:1–21.CrossRefGoogle Scholar
  7. 7.
    Kurano M, Darestani SG, Shinnakasu A, et al. mRNA expression of platelet activating factor receptor (PAFR) in peripheral blood mononuclear cells is associated with albuminuria and vascular dysfunction in patients with type 2 diabetes. Diabetes Res Clin Pract. 2018;136:124–33.CrossRefGoogle Scholar
  8. 8.
    Nakagawa T, Tanabe K, Croker BP, et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol. 2011;7(1):36–44.CrossRefGoogle Scholar
  9. 9.
    Tziomalos K, Athyros VG. Diabetic nephropathy: new risk factors and improvements in diagnosis. Rev Diabet Stud. 2015;12(1–2):110–8.CrossRefGoogle Scholar
  10. 10.
    Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–76.CrossRefGoogle Scholar
  11. 11.
    Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non–insulin-dependent diabetes mellitus. Kidney Int. 1999;55(1):1–28.CrossRefGoogle Scholar
  12. 12.
    Amini M, Safaei H, Aminorroaya A. The incidence of microalbuminuria and its associated risk factors in type 2 diabetic patients in Isfahan. Iran. Rev Diabet Stud. 2007;4(4):242–8.CrossRefGoogle Scholar
  13. 13.
    Larkins RG, Dunlop ME. The link between hyperglycaemia and diabetic nephropathy. Diabetologia. 1992;35(6):499–504.CrossRefGoogle Scholar
  14. 14.
    Haneda M, Kikkawa R, Togawa M, et al. High blood pressure is a risk factor for the development of microalbuminuria in Japanese subjects with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1992 6(3):181–185.CrossRefGoogle Scholar
  15. 15.
    Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13–8.CrossRefGoogle Scholar
  16. 16.
    Meguro S, Kabeya Y, Tanaka K, et al. Past obesity as well as present body weight status is a risk factor for diabetic nephropathy. Int J Endocrinol. 2013;2013:590569. Scholar
  17. 17.
    Appel GB, Radhakrishnan J, Avram MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003;26(5):1402–7.CrossRefGoogle Scholar
  18. 18.
    Vivian E, Mannebach C. Therapeutic approaches to slowing the progression of diabetic nephropathy—Is less best? Drugs Context. 2013;2013:1–12.CrossRefGoogle Scholar
  19. 19.
    Sonkodi S, Mogyorósi A. Treatment of diabetic nephropathy with angiotensin II blockers. Nephrol Dial Transp. 2003;18 Suppl 5:v21-3. Accessed Jan 11 2019.
  20. 20.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329(20):1456–62.CrossRefGoogle Scholar
  21. 21.
    Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci. 2017;18(5):1083.CrossRefGoogle Scholar
  22. 22.
    Dieter BP, Alicic RZ, Tuttle KR. GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. Am J Physiol Physiol. 2018;315(6):F1519–F15251525.CrossRefGoogle Scholar
  23. 23.
    Koya D, Campese VM. Statin use in patients with diabetes and kidney disease: the Japanese experience. J Atheroscler Thromb. 2013;20(5):407–24.CrossRefGoogle Scholar
  24. 24.
    Ting R-D, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study. Diabetes Care. 2012;35(2):218–25.CrossRefGoogle Scholar
  25. 25.
    Patel PS, Kearney JF. CD36 and platelet-activating factor receptor promote house dust mite allergy development. J Immunol. 2017;199(3):1184–95.CrossRefGoogle Scholar
  26. 26.
    Shiju TM, Mohan V, Balasubramanyam M, Viswanathan P. Soluble CD36 in plasma and urine: a plausible prognostic marker for diabetic nephropathy. J Diabetes Complications. 2015;29(3):400–6.CrossRefGoogle Scholar
  27. 27.
    Ruster C, Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci. 2008;13:944–55.CrossRefGoogle Scholar
  28. 28.
    Axelrad TW, Deo DD, Ottino P, et al. Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. FASEB J. 2004;18(3):568–70.CrossRefGoogle Scholar
  29. 29.
    Ding H-L, Xu M-T, Guo Y, et al. Effect of losartan on the mRNA expressions of MT3-MMP and TIMP-2 in diabetic kidneys. Rev Diabet Stud. 2005;2(4):216–216.CrossRefGoogle Scholar
  30. 30.
    Correa-Costa M, Andrade-Oliveira V, Braga TT, et al. Activation of platelet-activating factor receptor exacerbates renal inflammation and promotes fibrosis. Lab Invest. 2014;94(4):455–66.CrossRefGoogle Scholar
  31. 31.
    Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 2013;124(3):139–52.CrossRefGoogle Scholar
  32. 32.
    Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110(1):32–5.CrossRefGoogle Scholar
  33. 33.
    Ishii S, Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res. 2000;39(1):41–82.CrossRefGoogle Scholar
  34. 34.
    Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000;80(4):1669–99.CrossRefGoogle Scholar

Copyright information

© The Japan Diabetes Society 2019

Authors and Affiliations

  • Sahar Ghavidel Darestani
    • 1
  • Mihoko Kurano
    • 1
    Email author
  • Atsushi Shinnakasu
    • 1
  • Kiyoaki Yamamoto
    • 1
  • Yukari Dochi
    • 1
  • Kayo Uemura
    • 1
  • Yuko Ikeda
    • 1
  • Aiko Arimura
    • 1
  • Hiroshi Arimura
    • 1
  • Akira Kikuchi
    • 1
  • Hiroshi Hashiguchi
    • 1
  • Takahisa Deguchi
    • 1
  • Yoshihiko Nishio
    • 1
  1. 1.Department of Diabetes and Endocrine MedicineKagoshima University Graduate School of Medical and Dental SciencesKagoshimaJapan

Personalised recommendations